Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease (SWAP-AC)

NCT04006288 PHASE4 COMPLETED Results posted

Recent studies indicate that anti-factor-Xa inhibition with low-dose rivaroxaban may have a role in the reduction of ischemic recurrences in patients with atherosclerotic disease manifestations. The objectives of this investigation are to assess the feasibility of switching from a DAPT to DPI regimen and to compare the pharmacodynamic profiles of these treatment regimens. This will be a prospective study conducted in cohorts of patients with CAD on treatment per standard of care with DAPT. Patients will be randomized to either maintain DAPT or to DPI. DPI consists in treatment with aspirin (81mg/qd) plus rivaroxaban (2.5mg/bid).

Details

Lead sponsor	University of Florida
Phase	PHASE4
Status	COMPLETED
Enrolment	90
Start date	Fri Sep 06 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Mon May 16 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Coronary Artery Disease

Interventions

• Clopidogrel
• Prasugrel
• ticagrelor
• aspirin
• rivaroxaban

Countries

United States